Gefitinib (marketed as Iressa)
Information
FDA ALERT [6/2005]
FDA has approved new labeling for Iressa that states the medicine should be used only in
cancer patients who have already taken the medicine and whose doctor
believes it is helping them. New patients should not be given Iressa
because in a large study Iressa did not make people live longer.
There are other medicines for non-small cell lung cancer (NSCLC)
that have shown an ability to make people live longer.
This information reflects FDA’s preliminary analysis of data
concerning this drug. FDA is considering, but has not reached a
final conclusion about, this information. FDA intends to update this
sheet when additional information or analyses become available.
- Patient Information Sheet [PDF]
or [HTML]
-
Healthcare Professional
Information
-
Healthcare Professional Sheet
[PDF]
or [HTML]
Other Information
Information on the June 2005 FDA Alert
On June 17, 2005, FDA announced approval of new labeling for
gefitinib (Iressa) that limits the indication to cancer patients
who, in the opinion of their treating physician, are currently
benefiting, or have previously benefited, from gefitinib treatment.
In May 2003, FDA approved Iressa (gefitinib). Iressa is an
anticancer drug that inhibits an enzyme (tyrosine kinase) present in
lung cancer cells, as well as other cancers and normal tissues, that
appears to be important to the growth of cancer cells. Iressa has
been used as a single agent for the treatment of non-small cell lung
cancer (NSCLC) that has progressed after, or failed to respond to
two other types of chemotherapy (drugs used to kill cancer cells).
In addition to the new labeling, FDA has agreed to AstraZeneca's
proposal to limit distribution of this drug under a risk management
plan called the Iressa Access Program.
Background Information
Report Adverse Events to
MedWatch
Back
to Top
Back to Drug Specific
Information
PDF requires the free Adobe
Acrobat Reader
Date created: June 17, 2005 |